One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf

• https://x.com/RHEUMarampa/status/2062647198328701331/photo/1

Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits. The main reason was activity simply wasn’t documented using a validated index. You can’t target what you don’t measure. Abstr 0351 @ RheumNow #EULAR2026 #axSpA #PsA https://t.co/VAcoZfCXsR

• https://x.com/synovialjoints/status/2062797701712859211/photo/1

💉Do GLP-1 agonists improve DMARD persistence in PsA/axSpA? TriNetX real-world study (n=3,068): YES! Better b/tsDMARD persistence and lower stroke & mortality risk #POS0194 #EULAR2026 @rheumnow

⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage? Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males #POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh

• https://x.com/Nellziade/status/2062595567683793172/photo/1

📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients? Data from the RABBIT-SpA registry (n=2,236) confirms: 67% vs 73% with 2009 criteria Clinical arm rarely fulfilled #POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r

• https://x.com/Nellziade/status/2062594803481678047/photo/1

🔍 Do posterior element lesions progress over 10 years in axSpA? Data from the DESIR inception cohort (n=320) says RARELY! But baseline PE inflammation raises facet ankylosis risk ~70-fold #POS0189 #EULAR2026 @RheumNow https://t.co/PdwlPGjKqK

• https://x.com/Nellziade/status/2062594452556837170/photo/1

CyTOF reveals significant sexual dimorphism in monocyte populations in active #axSpA Women show reduced classical and non-classical monocytes vs healthy controls. Men do not show the same pattern. Sex is not just a demographic variable in AxSpA it is also an immunological one.

Ivarmacitinib (selective JAK1 inhibitor) significantly improved ASAS40 vs placebo in nr-#axSpA(39.7% vs 24.8%; p=0.006) at 12 weeks, sustained to 24 weeks. Another oral option for non-radiographic disease. Abstr OP0237 @RheumNow #EULAR2026

🧬 Does spine vs knee enthesis differ immunologically? Translational scRNAseq study: YES! Spine produces more IL-23 but shows attenuated IL-17 response vs knee #POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ

• https://x.com/Nellziade/status/2062550503393828865/photo/1

🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA? SPACE cohort (n=669): HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%) #OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l

• https://x.com/Nellziade/status/2062546844421373976/photo/1

🎗️ Do targeted therapies raise cancer risk in SpA? French nationwide cohort (n=56,591): NO In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological. #OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX

• https://x.com/Nellziade/status/2062545816187699690/photo/1

💉 Does ivarmacitinib (selective #JAK1i work in nr-axSpA? Phase 3 RCT (n=304): ASAS40 39.7% vs 24.8% placebo at week 12 with sustained benefit at week 24 #OP0237 #EULAR2026 @RheumNow https://t.co/kofXnPp6qQ

• https://x.com/Nellziade/status/2062545287885787380/photo/1